Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Pancreatic Ductal Adenocarcinoma

NCT06828328 is registered in ClinicalTrials.gov with Shanghai Juncell Therapeutics as lead sponsor.

NCT NCT06828328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06828328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Pancreatic Ductal Adenocarcinoma
Lead sponsor
Shanghai Juncell Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
February 10, 2025
Completion date
January 31, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancratic ductal adenocarcinoma, pancreatic cancer, treatment side effects, tumor infiltrating lymphocytes